Obstetrics and Gynaecology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/208

Filters

2010 1
1
1
Reset filters

Settings
Statistics
Citations
Author: Allen, David × Author: Rice, Gregory × End date: 2019 × Start date: 2010 ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
    Edgell, T ; Martin-Roussety, G ; Barker, G ; Autelitano, DJ ; Allen, D ; Grant, P ; Rice, GE (SPRINGER, 2010-07)
    PURPOSE: The primary hypothesis to be tested in this study was that the diagnostic performance (as assessed by the area under the receiver operator characteristic curve, AUC) of a multianalyte panel to correctly identify women with ovarian cancer was significantly greater than that for CA-125 alone. METHODS: A retrospective, case-control study (phase II biomarker trial) was conducted that involved 362 plasma samples obtained from women with ovarian cancer (n = 150) and healthy controls (n = 212). A multivariate classification model was developed that incorporated five biomarkers of ovarian cancer, CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8) from a modelling cohort (n = 179). The performance of the model was evaluated using an independent validation cohort (n = 183) and compared with of CA-125 alone. RESULTS: The AUC for the biomarker panel was significantly greater than the AUC for CA-125 alone for a validation cohort (p < 0.01) and an early stage disease cohort (i.e. Stages I and II; p < 0.01). At a threshold of 0.3, the sensitivity and specificity of the multianalyte panel were 94.1 and 91.3%, respectively, for the validation cohort and 92.3 and 91.3%, respectively for an early stage disease cohort. CONCLUSIONS: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone.